Market Place
Sourcing Support
LENZ Therapeutics to Participate in Upcoming Investor Conferences
12 Nov 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Reports Q3 2024 Financial Results
06 Nov 2024 //
GLOBENEWSWIRE
LENZ Therapeutics to Report Q3 Financial Results on Nov 6, 2024
30 Oct 2024 //
GLOBENEWSWIRE
Positive Phase 3 Data from CORXEL and LENZ in Presbyopia
27 Oct 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Announces FDA Acceptance Of LNZ100 Application
21 Oct 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Presents At Upcoming Ophthalmology Conferences
30 Sep 2024 //
GLOBENEWSWIRE
LENZ Therapeutics to Participate in Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
LENZ Submits NDA For LNZ100 Presbyopia Treatment To FDA
12 Aug 2024 //
GLOBENEWSWIRE
LENZ Therapeutics To Report Q2 2024 Financial Results On August 14
07 Aug 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
15 Jul 2024 //
GLOBENEWSWIRE
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
10 Jun 2024 //
GLOBENEWSWIRE
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
LENZ Q1 2024 Financials, Business Updates
08 May 2024 //
GLOBENEWSWIRE
LENZ Therapeutics Q1 2024 Results, Business Update On May 8
01 May 2024 //
GLOBENEWSWIRE
LENZ rallies presbyopia awareness eyecare professionals ahead of FDA submission
05 Apr 2024 //
ENDPTS
LENZ Thera Announces Positive Data from Phase 3 CLARITY Presbyopia Trials
03 Apr 2024 //
BUSINESSWIRE
LENZ to Host Investor Call to Discuss Results from the Ph 3 Presbyopia Trials
02 Apr 2024 //
BUSINESSWIRE
Graphite Bio Declares Dividend In Connection with Proposed Merger with Lenz
08 Mar 2024 //
BUSINESSWIRE
Graphite hands Nasdaq spot to presbyopia biotech Lenz as PhIII readouts loom
15 Nov 2023 //
ENDPTS
Gene editing biotech Graphite merges into vision loss biotech
15 Nov 2023 //
FIERCE BIOTECH
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
15 Nov 2023 //
BUSINESSWIRE
LENZ Therapeutics Announces $83.5 Million Series B Financing
07 Mar 2023 //
BUSINESSWIRE
Lenz eyes better vision than AbbVie, Orasis with $80M+ for three PhIII trials
07 Mar 2023 //
ENDPTS
LENZ Announces Topline Data from PhII Trial of LNZ100 & LNZ101
18 Oct 2022 //
BUSINESSWIRE
LENZ and JIXING Announce an Exclusive Greater China License Agreement
13 Apr 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.